J. Cui

发表

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

J. Christensen, B. Mroczkowski, L. Funk, 2011, Journal of medicinal chemistry.

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

Shinji Yamazaki, Gordon Alton, Pei-Pei Kung, 2007, Cancer research.

Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)

A. Drilon, A. Shaw, S. Ou, 2019, Annals of Oncology.

BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives.

Shu Liu, J. Cui, R. Fu, 2013, Bioorganic & medicinal chemistry letters.

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer

You Won Lee, Sung Sook Lee, A. Drilon, 2020, Clinical Cancer Research.

Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-bicyclic arginine surrogates.

J. Cui, S. Kemp, D. Siev, 2002, Bioorganic & medicinal chemistry letters.

Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of

J. Christensen, J. Cui, M. Tran-Dube, 2012, Journal of medicinal chemistry.

Stereocontrolled allylation of 2-amino-2-deoxy sugar derivatives by a free-radical procedure

J. Cui, D. Horton, 1998 .

Gene expression profiling of human promyelocytic leukemia HL-60 cell treated by ajoene

J. Cui, Mengsu Yang, Wen-xiu Huang, 2002 .

Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-dependent kinase 2 inhibitors.

J. Cui, Jennifer Zhang, Jennifer Zhang, 2003, Bioorganic & medicinal chemistry letters.

Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.

J. Christensen, J. Cui, M. Tran-Dube, 2013, Journal of medicinal chemistry.

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

J. Christensen, J. Cui, J. Cherrington, 2003, Cancer research.

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

Shinji Yamazaki, Tod Smeal, J. Christensen, 2012, Molecular Cancer Therapeutics.

Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.

J. Cui, 2014, Journal of medicinal chemistry.

Preclinical Development Sensitivity ofSelectedHumanTumorModels toPF-04217903 , a Novel Selective c-Met Kinase Inhibitor

J. Christensen, J. Cui, M. McTigue, 2012 .

Chapter Twenty-Five - Case History: Xalkori™ (Crizotinib), a Potent and Selective Dual Inhibitor of Mesenchymal Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) for Cancer Treatment

J. Cui, M. McTigue, M. Edwards, 2013 .

Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).

A. Drilon, S. Ou, A. Shaw, 2019, Journal of Clinical Oncology.

Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain.

Gareth J Waldron, R. Grimley, M. Andrews, 2018, Journal of medicinal chemistry.

Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications

J. Cui, 2007 .

Preliminary Clinical Activity of Repotrectinib (TPX‐0005) in Advanced ROS1 Fusion‐Positive Non‐Small Cell Lung Cancer: OA09

A. Drilon, A. Shaw, S. Ou, 2018, Journal of Thoracic Oncology.

Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors.

R. Grimley, J. Bilsland, J. Cui, 2019, Journal of medicinal chemistry.

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

J. Christensen, J. Cui, M. McTigue, 2012, Molecular Cancer Therapeutics.